Ruotolo G, Parlavecchia M, Taskinen M R, Galimberti G, Zoppo A, Le N A, Ragogna F, Micossi P, Pozza G
Department of Medicine (Laboratory of Lipoprotein Metabolism and Atherosclerosis), Scientific Institute H San Raffaele, University of Milan, Italy.
Diabetes Care. 1994 Jan;17(1):6-12. doi: 10.2337/diacare.17.1.6.
To characterize the effects of intraperitoneal insulin pump therapy on lipoprotein composition and lipolytic enzyme activity in patients with insulin-dependent diabetes mellitus (IDDM).
Ten IDDM patients were studied 3 times: when receiving conventional subcutaneous insulin therapy and at 3 and 9 months from the initiation of intraperitoneal insulin regimen. Ten nondiabetic subjects matched for age, sex, and body weight were studied as controls. Levels of cholesterol, triglycerides, apolipoprotein A-I (apoA-I) and B (apoB) were measured in total plasma and lipoprotein fractions (very-low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], low-density lipoprotein [LDL], and high-density lipoprotein [HDL]: HDL2 and HDL3). Postheparin plasma lipoprotein lipase and hepatic lipase activities were determined by an immunochemical method.
IDDM patients showed higher levels of HDL3 and lower levels of HDL2 particles during intraperitoneal insulin therapy in comparison with subcutaneous insulin therapy. Both cholesterol and apoA-I significantly increased in HDL3 and decreased in HDL2 during intraperitoneal treatment. Plasma total cholesterol significantly decreased in the diabetic patients at 3 months of intraperitoneal insulin therapy compared with both subcutaneous insulin regimen and control subjects. IDL triglyceride concentrations during intraperitoneal treatment were significantly lower than those seen with subcutaneous therapy. Furthermore, triglyceride:apoB ratio in VLDL and cholesterol:apoB ratio in LDL significantly decreased in IDDM patients treated by intraperitoneal insulin. A significant increase in the activity of hepatic lipase with intraperitoneal insulin therapy by 9 months compared with subcutaneous insulin therapy has been shown.
The increased activity of hepatic lipase after intraperitoneal insulin administration in IDDM patients appears to be one of the main determinants of lipoprotein changes observed, resulting in the normalization of lipoprotein composition during this mode of therapy. The normal inverse relationship between VLDL triglycerides and HDL cholesterol, which was not present in IDDM patients with subcutaneous therapy, was restored with intraperitoneal insulin regimen.
描述腹腔内胰岛素泵治疗对胰岛素依赖型糖尿病(IDDM)患者脂蛋白组成和脂解酶活性的影响。
对10例IDDM患者进行了3次研究:接受传统皮下胰岛素治疗时,以及开始腹腔内胰岛素治疗后的3个月和9个月。选取10名年龄、性别和体重匹配的非糖尿病受试者作为对照。测定了总血浆和脂蛋白组分(极低密度脂蛋白[VLDL]、中间密度脂蛋白[IDL]、低密度脂蛋白[LDL]和高密度脂蛋白[HDL]:HDL2和HDL3)中的胆固醇、甘油三酯、载脂蛋白A-I(apoA-I)和B(apoB)水平。采用免疫化学方法测定肝素后血浆脂蛋白脂肪酶和肝脂肪酶活性。
与皮下胰岛素治疗相比,IDDM患者在腹腔内胰岛素治疗期间HDL3水平较高,HDL2颗粒水平较低。腹腔内治疗期间,HDL3中的胆固醇和apoA-I均显著增加,HDL2中的则显著降低。与皮下胰岛素治疗方案和对照受试者相比,腹腔内胰岛素治疗3个月时糖尿病患者的血浆总胆固醇显著降低。腹腔内治疗期间IDL甘油三酯浓度显著低于皮下治疗。此外,腹腔内胰岛素治疗的IDDM患者中,VLDL中的甘油三酯:apoB比值和LDL中的胆固醇:apoB比值显著降低。与皮下胰岛素治疗相比,腹腔内胰岛素治疗9个月时肝脂肪酶活性显著增加。
IDDM患者腹腔内注射胰岛素后肝脂肪酶活性增加似乎是观察到的脂蛋白变化的主要决定因素之一,导致这种治疗方式下脂蛋白组成正常化。皮下治疗的IDDM患者中不存在的VLDL甘油三酯与HDL胆固醇之间正常的负相关关系,在腹腔内胰岛素治疗方案中得以恢复。